2020 Q4 Form 10-Q Financial Statement
#000086389421000003 Filed on February 10, 2021
Income Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| Revenue | $14.62M | $10.58M |
| YoY Change | 38.18% | 66.01% |
| Cost Of Revenue | $3.780M | $3.309M |
| YoY Change | 14.25% | 91.52% |
| Gross Profit | $10.84M | $7.269M |
| YoY Change | 49.08% | 56.52% |
| Gross Profit Margin | 74.14% | 68.72% |
| Selling, General & Admin | $4.382M | $3.754M |
| YoY Change | 16.74% | 13.95% |
| % of Gross Profit | 40.44% | 51.64% |
| Research & Development | $5.678M | $5.300M |
| YoY Change | 7.13% | 124.4% |
| % of Gross Profit | 52.39% | 72.91% |
| Depreciation & Amortization | $32.00K | $120.0K |
| YoY Change | -73.33% | 181.99% |
| % of Gross Profit | 0.3% | 1.65% |
| Operating Expenses | $10.06M | $9.053M |
| YoY Change | 11.11% | 60.07% |
| Operating Profit | $19.19M | -$1.784M |
| YoY Change | -1175.28% | 76.37% |
| Interest Expense | $1.189M | $1.141M |
| YoY Change | 4.18% | -10.72% |
| % of Operating Profit | 6.2% | |
| Other Income/Expense, Net | -$1.881M | -$1.597M |
| YoY Change | 17.76% | 52.93% |
| Pretax Income | $17.31M | -$3.382M |
| YoY Change | -611.73% | 64.46% |
| Income Tax | $78.30K | -$76.74K |
| % Of Pretax Income | 0.45% | |
| Net Earnings | $17.23M | -$3.305M |
| YoY Change | -621.25% | 53.81% |
| Net Earnings / Revenue | 117.86% | -31.24% |
| Basic Earnings Per Share | $0.25 | -$0.05 |
| Diluted Earnings Per Share | $0.23 | -$0.05 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 70.31M | 65.04M |
| Diluted Shares Outstanding | 75.80M | 65.04M |
Balance Sheet
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $30.90M | $4.200M |
| YoY Change | 635.71% | -53.33% |
| Cash & Equivalents | $30.92M | $4.175M |
| Short-Term Investments | ||
| Other Short-Term Assets | $3.300M | $2.100M |
| YoY Change | 57.14% | 75.0% |
| Inventory | $6.666M | $4.595M |
| Prepaid Expenses | ||
| Receivables | $4.156M | $5.970M |
| Other Receivables | $2.500M | $0.00 |
| Total Short-Term Assets | $47.57M | $16.82M |
| YoY Change | 182.87% | 9.19% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $288.0K | $336.2K |
| YoY Change | -14.33% | -7.13% |
| Goodwill | $6.879M | |
| YoY Change | ||
| Intangibles | $4.102M | $20.09M |
| YoY Change | -79.58% | -1.52% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $10.20M | $675.9K |
| YoY Change | 1409.08% | -92.73% |
| Total Long-Term Assets | $25.23M | $37.72M |
| YoY Change | -33.11% | 2.22% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $47.57M | $16.82M |
| Total Long-Term Assets | $25.23M | $37.72M |
| Total Assets | $72.80M | $54.54M |
| YoY Change | 33.49% | 4.28% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.275M | $3.800M |
| YoY Change | -13.82% | 80.95% |
| Accrued Expenses | $6.500M | $6.500M |
| YoY Change | 0.0% | 150.0% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $7.300M | $6.600M |
| YoY Change | 10.61% | 34.69% |
| Total Short-Term Liabilities | $17.06M | $16.90M |
| YoY Change | 0.96% | 73.47% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $6.000M | $6.700M |
| YoY Change | -10.45% | 293.52% |
| Other Long-Term Liabilities | $18.24K | $35.91K |
| YoY Change | -49.2% | 19.69% |
| Total Long-Term Liabilities | $18.24K | $35.91K |
| YoY Change | -49.2% | -97.93% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $17.06M | $16.90M |
| Total Long-Term Liabilities | $18.24K | $35.91K |
| Total Liabilities | $24.04M | $24.90M |
| YoY Change | -3.45% | 61.13% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$71.96M | -$73.52M |
| YoY Change | -2.12% | |
| Common Stock | $740.9K | $672.2K |
| YoY Change | 10.22% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $7.807M | $7.807M |
| YoY Change | 0.0% | |
| Treasury Stock Shares | $2.184M | $2.184M |
| Shareholders Equity | $48.75M | $29.64M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $72.79M | $54.50M |
| YoY Change | 33.56% | 4.14% |
Cashflow Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $17.23M | -$3.305M |
| YoY Change | -621.25% | 53.81% |
| Depreciation, Depletion And Amortization | $32.00K | $120.0K |
| YoY Change | -73.33% | 181.99% |
| Cash From Operating Activities | $659.2K | -$2.511M |
| YoY Change | -126.26% | 66.65% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $7.186K | $21.81K |
| YoY Change | -67.05% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $15.00M | |
| YoY Change | ||
| Cash From Investing Activities | $14.99M | -$21.81K |
| YoY Change | -68852.3% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 1.681M | 412.1K |
| YoY Change | 307.82% | -93.87% |
| NET CHANGE | ||
| Cash From Operating Activities | 659.2K | -2.511M |
| Cash From Investing Activities | 14.99M | -21.81K |
| Cash From Financing Activities | 1.681M | 412.1K |
| Net Change In Cash | 17.33M | -2.120M |
| YoY Change | -917.51% | -140.62% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $659.2K | -$2.511M |
| Capital Expenditures | $7.186K | $21.81K |
| Free Cash Flow | $652.1K | -$2.532M |
| YoY Change | -125.75% | 68.09% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | us-gaap |
Accretion Expense
AccretionExpense
|
259178 | |
| CY2020Q4 | us-gaap |
Accretion Expense
AccretionExpense
|
602858 | |
| CY2020Q4 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2020Q4 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--09-30 | |
| CY2020Q4 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2020Q4 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
| CY2020Q4 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-12-31 | |
| CY2020Q4 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2020Q4 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000863894 | |
| CY2021Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
71911903 | |
| CY2020Q4 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2020Q4 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2020Q4 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2020Q4 | dei |
Entity Registrant Name
EntityRegistrantName
|
VERU INC. | |
| CY2020Q4 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2020Q4 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2020Q4 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.01 par value per share | |
| CY2020Q4 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2020Q4 | dei |
Trading Symbol
TradingSymbol
|
VERU | |
| CY2020Q3 | us-gaap |
Accounts Receivable Gross
AccountsReceivableGross
|
5332786 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Gross
AccountsReceivableGross
|
4253681 | |
| CY2020Q3 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
5227237 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Net
AccountsReceivableNet
|
4155792 | |
| CY2020Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5227237 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
4155792 | |
| CY2020Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2812673 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3274856 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
1606045 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1005282 | |
| CY2020Q3 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
14074740 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
12341954 | |
| CY2020Q3 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
49832 | |
| CY2020Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
45791 | |
| CY2020Q4 | us-gaap |
Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
|
18410158 | |
| CY2020Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3542533 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3572214 | |
| CY2020Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-581519 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-581519 | |
| CY2020Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
126971518 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
128360202 | |
| CY2019Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
614498 | |
| CY2020Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
785297 | |
| CY2020Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
25643 | |
| CY2020Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
25643 | |
| CY2019Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
|
0 | |
| CY2020Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
|
0 | |
| CY2019Q4 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
20261 | |
| CY2020Q4 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
13465 | |
| CY2019Q4 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
861986 | |
| CY2020Q4 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
572860 | |
| CY2019Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
79000 | |
| CY2020Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
60000 | |
| CY2020Q4 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1400000 | |
| CY2020Q3 | us-gaap |
Assets Current
AssetsCurrent
|
27014690 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
47567306 | |
| CY2020Q4 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 1 – Basis of Presentation</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, these statements do not include all the disclosures normally required by U.S. GAAP for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="display: inline;">September 30, 2020</font><font style="display: inline;">. The accompanying condensed consolidated balance sheet as of </font><font style="display: inline;">September 30, 2020</font><font style="display: inline;"> has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations and cash flows for the three months ended December 31, 2020 are not necessarily indicative of the results to be expected for any future period or for the fiscal year ending </font><font style="display: inline;">September 30, 20</font><font style="display: inline;">21. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Principles of consolidation and nature of operations</font><font style="display: inline;">: Veru Inc. is </font><font style="display: inline;color:#000000;">referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” </font><font style="display: inline;">The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Aspen Park Pharmaceuticals, Inc. (APP) and The Female Health Company Limited, and The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”), and The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”). All significant intercompany transactions and accounts have been eliminated in consolidation. The Company is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers. The Company has multiple drug products under clinical development. During fiscal 2020, the Sexual Health Business segment also included PREBOOST® 4% benzocaine medicated individual wipe for the treatment of premature ejaculation. The PREBOOST® business was sold on December 8, 2020. See Note 3 for additional information. Most of the Company’s net revenues during the three months ended December 31, 2020 and 2019 were derived from sales of FC2. </font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">: </font><font style="display: inline;">Certain prior period amounts on the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Other comprehensive income (loss)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income (loss). Although certain changes in assets and liabilities, such as foreign currency translation adjustments, are reported as a separate component of the equity section of the accompanying unaudited condensed consolidated balance sheets, these items, along with net income (loss), are components of other comprehensive loss. For the three months ended December 31, 2020 and 2019, comprehensive income (loss) is equivalent to the reported net income (loss).</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Recently adopted accounting pronouncements</font><font style="display: inline;">: In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses (Topic 326). This ASU introduces a new accounting model, the Current Expected Credit Losses model (CECL), which could result in earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model requires the Company to use a forward-looking expected credit loss impairment methodology for the recognition of credit losses for financial instruments at the time the financial asset is originated or acquired. The expected credit losses are adjusted each period for changes in expected lifetime credit losses. This model replaces the multiple existing impairment models in current U.S. GAAP, which generally require that a loss be incurred before it is recognized. The new standard also applies to receivables arising from revenue transactions such as accounts receivable. The Company adopted ASU 2016-13 on a modified-retrospective basis effective October 1, 2020. The adoption of ASU 2016-13 did not impact our consolidated financial statements and related disclosures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment. The purpose of ASU 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The Company adopted ASU 2017-04 on a prospective basis effective October 1, 2020. The adoption of ASU 2017-04 did not impact our consolidated financial statements and related disclosures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Change to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The Company adopted ASU 2018-13 on a retrospective basis effective October 1, 2020. The adoption of ASU 2018-13 did not impact our financial position, results of operations, or cash flows as it modified disclosure requirements only.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p><font size="1"> </font></p> </div> </div> | |
| CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
6295152 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4174957 | |
| CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
13588778 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
30921496 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2120195 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
17332718 | |
| CY2020Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
154000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
154000000 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
72047385 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
74090607 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
69863681 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
71906903 | |
| CY2020Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
720474 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
740906 | |
| CY2019Q4 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
3308921 | |
| CY2020Q4 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
3780356 | |
| CY2020Q3 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
9466800 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
9429298 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-152610 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
37502 | |
| CY2020Q3 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1319164 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
945886 | |
| CY2020Q3 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
74724 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
74724 | |
| CY2020Q3 | us-gaap |
Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
|
850248 | |
| CY2020Q3 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
24785980 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
22642414 | |
| CY2020Q3 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
9392076 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
9354574 | |
| CY2020Q3 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
10711240 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
10300460 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
7677224 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
|
11618351 | |
| CY2019Q4 | us-gaap |
Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
|
-394000 | |
| CY2020Q4 | us-gaap |
Gain Loss On Derivative Instruments Held For Trading Purposes Net
GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet
|
-604000 | |
| CY2019Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.05 | |
| CY2020Q4 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.25 | |
| CY2019Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.05 | |
| CY2020Q4 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.23 | |
| CY2020Q4 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2020Q4 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
|
-64290 | |
| CY2019Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
394000 | |
| CY2020Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
604000 | |
| CY2019Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
3625000 | |
| CY2019Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
4019000 | |
| CY2020Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
4182000 | |
| CY2020Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
4786000 | |
| CY2019Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
1480 | |
| CY2020Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
939 | |
| CY2019Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
1300 | |
| CY2020Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
4598 | |
| CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
2178 | |
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
2178 | |
| CY2020Q3 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1390 | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.1390 | |
| CY2020Q3 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y4M24D | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y2M12D | |
| CY2020Q3 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1047873 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
297619 | |
| CY2020Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2900000 | |
| CY2019Q4 | us-gaap |
Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
|
0 | |
| CY2020Q4 | us-gaap |
Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
|
0 | |
| CY2020Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1852127 | |
| CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
6878932 | |
| CY2019Q4 | us-gaap |
Gross Profit
GrossProfit
|
7269095 | |
| CY2020Q4 | us-gaap |
Gross Profit
GrossProfit
|
10836633 | |
| CY2019Q4 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3381844 | |
| CY2020Q4 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
17306003 | |
| CY2019Q4 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-76743 | |
| CY2020Q4 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
78302 | |
| CY2019Q4 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
592710 | |
| CY2020Q4 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-1732786 | |
| CY2019Q4 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
42554 | |
| CY2020Q4 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-32570 | |
| CY2019Q4 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
2730 | |
| CY2020Q4 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
1952 | |
| CY2019Q4 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
703123 | |
| CY2019Q4 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
642764 | |
| CY2019Q4 | us-gaap |
Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
|
-394000 | |
| CY2020Q4 | us-gaap |
Increase Decrease In Derivative Assets And Liabilities
IncreaseDecreaseInDerivativeAssetsAndLiabilities
|
-604000 | |
| CY2019Q4 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1099906 | |
| CY2019Q4 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
209177 | |
| CY2020Q4 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
1025580 | |
| CY2020Q3 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
6800000 | |
| CY2020Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
4400000 | |
| CY2020Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
5752127 | |
| CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
4102381 | |
| CY2019Q4 | us-gaap |
Interest Expense
InterestExpense
|
1141425 | |
| CY2020Q4 | us-gaap |
Interest Expense
InterestExpense
|
1189183 | |
| CY2020Q4 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1096390 | |
| CY2020Q3 | us-gaap |
Inventory Net
InventoryNet
|
6704134 | |
| CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
6665908 | |
| CY2019Q4 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
151922 | |
| CY2020Q4 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
9138 | |
| CY2019Q4 | us-gaap |
Lease Cost
LeaseCost
|
126716 | |
| CY2020Q4 | us-gaap |
Lease Cost
LeaseCost
|
132144 | |
| CY2019Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
114000 | |
| CY2020Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
143000 | |
| CY2020Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1352315 | |
| CY2020Q3 | us-gaap |
Liabilities
Liabilities
|
21432359 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
24040344 | |
| CY2020Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
51543675 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
72788477 | |
| CY2020Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14727141 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
17062532 | |
| CY2019Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
412114 | |
| CY2020Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1680663 | |
| CY2019Q4 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-21807 | |
| CY2020Q4 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
14992814 | |
| CY2019Q4 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2510502 | |
| CY2020Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
17227701 | |
| CY2020Q4 | us-gaap |
Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
|
5000000 | |
| CY2019Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1597451 | |
| CY2020Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1881154 | |
| CY2020Q4 | us-gaap |
Nontrade Receivables Current
NontradeReceivablesCurrent
|
2500000 | |
| CY2020Q4 | us-gaap |
Nontrade Receivables Noncurrent
NontradeReceivablesNoncurrent
|
2500000 | |
| CY2020Q4 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | |
| CY2019Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
9053488 | |
| CY2020Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
10059634 | |
| CY2019Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1784393 | |
| CY2020Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
19187157 | |
| CY2019Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
132574 | |
| CY2020Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
135326 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
586769 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
622733 | |
| CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
990020 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
899121 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1260553 | |
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.1150 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.1150 | |
| CY2020Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y7M6D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y4M24D | |
| CY2020Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
22980 | |
| CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
18239 | |
| CY2019Q4 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-1141425 | |
| CY2019Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-62026 | |
| CY2020Q4 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-87971 | |
| CY2019Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
21807 | |
| CY2020Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7186 | |
| CY2020Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1494541 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3324110 | |
| CY2020Q4 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">: </font><font style="display: inline;">Certain prior period amounts on the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p><font size="1"> </font></p> </div> </div> | |
| CY2020Q4 | us-gaap |
Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
|
15000000 | |
| CY2019Q4 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
836780 | |
| CY2020Q4 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
1061442 | |
| CY2020Q4 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
623819 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3855224 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3860211 | |
| CY2020Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
312691 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
287997 | |
| CY2019Q4 | us-gaap |
Sublease Income
SubleaseIncome
|
44844 | |
| CY2020Q4 | us-gaap |
Sublease Income
SubleaseIncome
|
44845 | |
| CY2019Q4 | us-gaap |
Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
|
423366 | |
| CY2019Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5299974 | |
| CY2020Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5677754 | |
| CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-89192552 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-71964851 | |
| CY2019Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
10578016 | |
| CY2020Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
14616989 | |
| CY2019Q4 | us-gaap |
Revenues
Revenues
|
10578016 | |
| CY2020Q4 | us-gaap |
Revenues
Revenues
|
14616989 | |
| CY2019Q4 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1229926 | |
| CY2019Q4 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
3753514 | |
| CY2020Q4 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
4381880 | |
| CY2019Q4 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
614498 | |
| CY2019Q4 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
1863 | |
| CY2020Q4 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
1863 | |
| CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
32333136 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
29642533 | |
| CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
30111316 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
48748133 | |
| CY2019Q4 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
614498 | |
| CY2020Q4 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
785297 | |
| CY2020Q4 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
623819 | |
| CY2020Q3 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
2183704 | |
| CY2020Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
2183704 | |
| CY2020Q3 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
7806605 | |
| CY2020Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
7806605 | |
| CY2019Q4 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
33465 | |
| CY2020Q4 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
36683 | |
| CY2020Q4 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
5485448 | |
| CY2019Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
65038511 | |
| CY2020Q4 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
75799037 | |
| CY2019Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
65038511 | |
| CY2020Q4 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
70313589 | |
| CY2020Q3 | veru |
Allowance For Sales And Payment Term Discounts
AllowanceForSalesAndPaymentTermDiscounts
|
79906 | |
| CY2020Q4 | veru |
Allowance For Sales And Payment Term Discounts
AllowanceForSalesAndPaymentTermDiscounts
|
72246 | |
| CY2020Q4 | veru |
Cares Act Effective Income Tax Rate Reconciliation Effect Of Paycheck Protection Program Funds
CaresActEffectiveIncomeTaxRateReconciliationEffectOfPaycheckProtectionProgramFunds
|
95886 | |
| CY2020Q4 | veru |
Deferred Tax Assets Foreign Capital Allowance
DeferredTaxAssetsForeignCapitalAllowance
|
113522 | |
| CY2020Q3 | veru |
Deferred Tax Liabilities Developed Technology
DeferredTaxLiabilitiesDevelopedTechnology
|
369237 | |
| CY2020Q3 | veru |
Deferred Tax Liabilities In Process R And D
DeferredTaxLiabilitiesInProcessRAndD
|
882427 | |
| CY2020Q4 | veru |
Deferred Tax Liabilities In Process R And D
DeferredTaxLiabilitiesInProcessRAndD
|
882427 | |
| CY2019Q4 | veru |
Depreciation And Other Amortization
DepreciationAndOtherAmortization
|
116623 | |
| CY2020Q4 | veru |
Depreciation And Other Amortization
DepreciationAndOtherAmortization
|
91783 | |
| CY2020Q4 | veru |
Effective Income Tax Rate Reconciliation Effect Of Warrants Exercised
EffectiveIncomeTaxRateReconciliationEffectOfWarrantsExercised
|
-2038919 | |
| CY2019Q4 | veru |
Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
|
50451 | |
| CY2020Q4 | veru |
Income Tax Reconciliation Effect Of Global Intangible Low Taxed Income
IncomeTaxReconciliationEffectOfGlobalIntangibleLowTaxedIncome
|
125145 | |
| CY2019Q4 | veru |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-53284 | |
| CY2019Q4 | veru |
Operating Lease Right Of Use Assets Non Cash Change
OperatingLeaseRightOfUseAssetsNonCashChange
|
76147 | |
| CY2020Q2 | veru |
Proceeds From Ppp Loan Cares Act
ProceedsFromPppLoanCaresAct
|
540000 | |
| CY2020Q4 | veru |
Product Liability Insurance Coverage Amount
ProductLiabilityInsuranceCoverageAmount
|
10000000 | |
| CY2020Q3 | veru |
Residual Royalty Agreement Current
ResidualRoyaltyAgreementCurrent
|
1100193 | |
| CY2020Q4 | veru |
Residual Royalty Agreement Current
ResidualRoyaltyAgreementCurrent
|
1938817 | |
| CY2020Q3 | veru |
Residual Royalty Agreement Noncurrent
ResidualRoyaltyAgreementNoncurrent
|
5617494 | |
| CY2020Q4 | veru |
Stock Issued During Period Shares Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodSharesStockOptionsExercisedCashlessExercise
|
0 |
